Drugs / ZKLJ02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07638098 | Aug → Nov 2025 | — | Yunnan Zhongke Longjin Biotechnology Co.,Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZKLJ02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07638098 ↗ |
| Route | Intravenous | “administer intravenously” NCT07638098 ↗ |